Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma

Cell & Bioscience

Hong Shan¹  Junying Zhu²  Lizhu Wang³  Yaqin Zhang³  Weijie Dong⁴  Xinjian Wu⁴ 

[1] Department of Interventional Medicine, The 5th Affiliated Hospital of Sun Yat-sen University;Department of Radiology, The 3rd Affiliated Hospital of Sun Yat-sen University;Department of Radiology, The 5th Affiliated Hospital of Sun Yat-sen University;Neurosurgery Department, The 1st Affiliated Hospital of Sun Yat-sen University;

关键词: DIPG;    EZH2 inhibitor;    BET inhibitor;    Epigenetics;    Tumor therapy;   

DOI  :  10.1186/s13578-017-0184-0

来源: DOAJ

【 摘 要 】

Abstract Background Diffuse intrinsic pontine glioma is an infiltrative, often high-grade glioma of the brainstem that is not amenable to surgical resection. The current treatment of DIPG by radiation therapy showed dramatically improvement of patient’s condition, however, the tumor recurs rapidly. More and more studies are focused on the genetic and epigenetic drivers of DIPGs, which may provide more and more novel therapy target for DIPG. EZH2 has been proved to be a potential therapeutic target for H3K27M-mutant pediatric gliomas recently. Meanwhile, BET family protein is a hot target in many different types of cancers, including DIPG. In this study, we performed the treatment of both EZH2 and BET inhibitor for DIPG cells. Results The combination of these two inhibitors exhibited better inhibition of the tumor growth both in vitro and in vivo compared to use the inhibitor individually. This inhibition was performed by blocking the proliferation and promoting the cell apoptosis. Meanwhile, combination treatment of these two inhibitors would also affect the epigenetic markers which were abnormal in the tumors of the certain set of genes. Conclusion Thus we provided a novel therapy strategy for clinical treatment of DIPG.

【 授权许可】

Unknown